• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分析 siRNA 中非环核苷修饰发现,第 1 位的敏感性可通过体外和体内 5'端磷酸化得到恢复。

Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo.

机构信息

Sirna Therapeutics, a wholly owned subsidiary of Merck and Co., 1700 Owens St, 4th Floor, San Francisco, CA 94158, USA.

出版信息

Nucleic Acids Res. 2010 Jan;38(2):660-71. doi: 10.1093/nar/gkp913. Epub 2009 Nov 16.

DOI:10.1093/nar/gkp913
PMID:19917641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2811019/
Abstract

Small interfering RNAs (siRNAs) are short, double-stranded RNAs that use the endogenous RNAi pathway to mediate gene silencing. Phosphorylation facilitates loading of a siRNA into the Ago2 complex and subsequent cleavage of the target mRNA. In this study, 2', 3' seco nucleoside modifications, which contain an acylic ribose ring and are commonly called unlocked nucleic acids (UNAs), were evaluated at all positions along the guide strand of a siRNA targeting apolipoprotein B (ApoB). UNA modifications at positions 1, 2 and 3 were detrimental to siRNA activity. UNAs at positions 1 and 2 prevented phosphorylation by Clp1 kinase, abrogated binding to Ago2, and impaired Ago2-mediated cleavage of the mRNA target. The addition of a 5'-terminal phosphate to siRNA containing a position 1 UNA restored ApoB mRNA silencing, Ago2 binding, and Ago2 mediated cleavage activity. Position 1 UNA modified siRNA containing a 5'-terminal phosphate exhibited a partial restoration of siRNA silencing activity in vivo. These data reveal the complexity of interpreting the effects of chemical modification on siRNA activity, and exemplify the importance of using multiple biochemical, cell-based and in vivo assays to rationally design chemically modified siRNA destined for therapeutic use.

摘要

小干扰 RNA(siRNA)是短的双链 RNA,利用内源性 RNAi 途径介导基因沉默。磷酸化有助于将 siRNA 加载到 Ago2 复合物中,并随后切割靶 mRNA。在这项研究中,2'、3' 位非环核苷修饰物(含有非环核糖环,通常称为非锁核酸(UNA))在靶向载脂蛋白 B(ApoB)的 siRNA 的引导链上的所有位置进行了评估。在位置 1、2 和 3 的 UNA 修饰对 siRNA 活性有害。位置 1 和 2 的 UNAs 阻止了 Clp1 激酶的磷酸化,破坏了与 Ago2 的结合,并损害了 Ago2 介导的 mRNA 靶标切割。在含有位置 1 UNA 的 siRNA 中添加 5'-末端磷酸基团恢复了 ApoB mRNA 沉默、Ago2 结合和 Ago2 介导的切割活性。含有 5'-末端磷酸基团的位置 1 UNA 修饰的 siRNA 在体内显示出部分恢复 siRNA 沉默活性。这些数据揭示了解释化学修饰对 siRNA 活性影响的复杂性,并说明了使用多种生化、基于细胞和体内测定来合理设计用于治疗用途的化学修饰 siRNA 的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/65ccf5a5b383/gkp913f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/7fc000c7d4aa/gkp913f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/d471743b8704/gkp913f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/6716f76e1fe9/gkp913f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/65ccf5a5b383/gkp913f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/7fc000c7d4aa/gkp913f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/d471743b8704/gkp913f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/6716f76e1fe9/gkp913f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d32/2811019/65ccf5a5b383/gkp913f4.jpg

相似文献

1
Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo.分析 siRNA 中非环核苷修饰发现,第 1 位的敏感性可通过体外和体内 5'端磷酸化得到恢复。
Nucleic Acids Res. 2010 Jan;38(2):660-71. doi: 10.1093/nar/gkp913. Epub 2009 Nov 16.
2
Re-Engineering RNA Molecules into Therapeutic Agents.将 RNA 分子重建成治疗剂。
Acc Chem Res. 2019 Apr 16;52(4):1036-1047. doi: 10.1021/acs.accounts.8b00650. Epub 2019 Mar 26.
3
5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates.5'-(E)-乙烯基膦酸酯:一种稳定的磷酸类似物,可以提高 siRNA-GalNAc 缀合物的 RNAi 活性。
Chembiochem. 2016 Jun 2;17(11):985-9. doi: 10.1002/cbic.201600130. Epub 2016 Apr 28.
4
In vivo activity and duration of short interfering RNAs containing a synthetic 5'-phosphate.含合成 5'-磷酸的短干扰 RNA 的体内活性和持续时间。
Nucleic Acid Ther. 2012 Apr;22(2):90-5. doi: 10.1089/nat.2011.0333. Epub 2012 Mar 8.
5
Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme.含核糖二氟甲苯基核苷酸的寡核糖核苷酸的晶体结构、稳定性及体外RNA干扰活性:对人RNA诱导沉默复合体AGO2酶底物需求的深入了解
Nucleic Acids Res. 2007;35(19):6424-38. doi: 10.1093/nar/gkm664. Epub 2007 Sep 18.
6
mRNA knockdown by single strand RNA is improved by chemical modifications.通过化学修饰可以提高单链 RNA 对 mRNA 的敲低作用。
Nucleic Acids Res. 2012 May;40(9):4125-36. doi: 10.1093/nar/gkr1301. Epub 2012 Jan 16.
7
siRNA potency enhancement via chemical modifications of nucleotide bases at the 5'-end of the siRNA guide strand.通过化学修饰 siRNA 引导链 5'-端的核苷酸碱基来增强 siRNA 的效力。
RNA. 2021 Feb;27(2):163-173. doi: 10.1261/rna.073783.119. Epub 2020 Nov 11.
8
Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes.乘客链切割有助于将小干扰RNA组装到含Ago2的RNA干扰酶复合物中。
Cell. 2005 Nov 18;123(4):607-20. doi: 10.1016/j.cell.2005.08.044. Epub 2005 Nov 3.
9
Amide-Modified RNA: Using Protein Backbone to Modulate Function of Short Interfering RNAs.酰胺修饰 RNA:利用蛋白质骨架调节短干扰 RNA 的功能。
Acc Chem Res. 2020 Sep 15;53(9):1782-1790. doi: 10.1021/acs.accounts.0c00249. Epub 2020 Jul 13.
10
Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.利用解锁核酸(UNA)提高小干扰RNA(siRNA)在体外和体内的性能。
Mol Biosyst. 2010 May;6(5):862-70. doi: 10.1039/b918869j. Epub 2010 Feb 9.

引用本文的文献

1
Chemical Modifications in Nucleic Acid Therapeutics.核酸疗法中的化学修饰
Methods Mol Biol. 2025;2965:57-126. doi: 10.1007/978-1-0716-4742-4_3.
2
siRNA as a criterion in host immunity and cancer immunotherapy: modulating factors and nano-conjugate based approach for intervention.小干扰RNA作为宿主免疫和癌症免疫治疗的一个标准:调节因子及基于纳米共轭物的干预方法
Int J Biol Sci. 2025 Jul 28;21(11):5116-5134. doi: 10.7150/ijbs.109637. eCollection 2025.
3
Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges.

本文引用的文献

1
C3PO, an endoribonuclease that promotes RNAi by facilitating RISC activation.C3PO,一种通过促进RNA诱导沉默复合体(RISC)激活来促进RNA干扰(RNAi)的核糖核酸酶。
Science. 2009 Aug 7;325(5941):750-3. doi: 10.1126/science.1176325.
2
Binding and cleavage specificities of human Argonaute2.人类 Argonaute2 的结合和切割特异性
J Biol Chem. 2009 Sep 18;284(38):26017-28. doi: 10.1074/jbc.M109.010835. Epub 2009 Jul 22.
3
A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity.
靶向 RNA 的合成寡核苷酸:临床成功带来新的挑战。
Cell Chem Biol. 2024 Jan 18;31(1):125-138. doi: 10.1016/j.chembiol.2023.09.005. Epub 2023 Oct 6.
4
Acyclic ()-glycol nucleic acid (-GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency.无环()-乙二醇核酸(-GNA)修饰的 siRNA 提高了 RNAi 治疗的安全性,同时保持了效力。
RNA. 2023 Apr;29(4):402-414. doi: 10.1261/rna.079526.122. Epub 2023 Feb 1.
5
Specificity of oligonucleotide gene therapy (OGT) agents.寡核苷酸基因治疗(OGT)药物的特异性。
Theranostics. 2022 Oct 9;12(16):7132-7157. doi: 10.7150/thno.77830. eCollection 2022.
6
Role of a "Magic" Methyl: 2'-Deoxy-2'-α-F-2'-β--methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5'-Phosphate Mimics and Mitigation of Off-Target Effects.“魔法”甲基的作用:2'-脱氧-2'-α-F-2'-β--甲基嘧啶核苷酸通过与 5'-磷酸类似物的协同作用和减轻脱靶效应来调节 RNA 干扰活性。
J Am Chem Soc. 2022 Aug 17;144(32):14517-14534. doi: 10.1021/jacs.2c01679. Epub 2022 Aug 3.
7
Chemical strategies for strand selection in short-interfering RNAs.短干扰RNA中链选择的化学策略。
RSC Adv. 2021 Jan 11;11(4):2415-2426. doi: 10.1039/d0ra07747j. eCollection 2021 Jan 6.
8
Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity.结构受限的膦酸酯核苷酸键合会影响寡核苷酸-酶相互作用,并调节 siRNA 的活性和等位基因特异性。
Nucleic Acids Res. 2021 Dec 2;49(21):12069-12088. doi: 10.1093/nar/gkab1126.
9
Development of siRNA Therapeutics for the Treatment of Liver Diseases.用于治疗肝脏疾病的 siRNA 疗法的开发。
Methods Mol Biol. 2021;2282:57-75. doi: 10.1007/978-1-0716-1298-9_5.
10
siRNAs containing 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2'-F-NMC NTPs.含 2'-氟代甲基碳桥环核苷酸(2'-F-NMC)的 siRNAs:体外和体内 RNAi 活性以及线粒体聚合酶不能掺入 2'-F-NMC NTP。
Nucleic Acids Res. 2021 Mar 18;49(5):2435-2449. doi: 10.1093/nar/gkab050.
一项大规模化学修饰筛选确定了生成具有高活性、高稳定性和低毒性的小干扰RNA的设计规则。
Nucleic Acids Res. 2009 May;37(9):2867-81. doi: 10.1093/nar/gkp106. Epub 2009 Mar 12.
4
MicroRNA-like off-target transcript regulation by siRNAs is species specific.小干扰RNA(siRNA)对类微小RNA脱靶转录本的调控具有物种特异性。
RNA. 2009 Feb;15(2):308-15. doi: 10.1261/rna.1326809.
5
Unlocked nucleic acid (UNA) and UNA derivatives: thermal denaturation studies.解锁核酸(UNA)及其衍生物:热变性研究。
Nucleic Acids Symp Ser (Oxf). 2008(52):133-4. doi: 10.1093/nass/nrn068.
6
Structure of the guide-strand-containing argonaute silencing complex.含引导链的AGO沉默复合体的结构
Nature. 2008 Nov 13;456(7219):209-13. doi: 10.1038/nature07315. Epub 2008 Aug 27.
7
Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity.小干扰RNA双链体的链特异性5'-O-甲基化控制引导链选择和靶向特异性。
RNA. 2008 Feb;14(2):263-74. doi: 10.1261/rna.789808. Epub 2007 Dec 19.
8
Comparison of multiple DNA dyes for real-time PCR: effects of dye concentration and sequence composition on DNA amplification and melting temperature.用于实时PCR的多种DNA染料的比较:染料浓度和序列组成对DNA扩增及解链温度的影响
Nucleic Acids Res. 2007;35(19):e127. doi: 10.1093/nar/gkm671. Epub 2007 Sep 26.
9
Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA.碱基修饰对短干扰RNA的结构、热力学稳定性及基因沉默活性的影响
RNA. 2007 Aug;13(8):1301-16. doi: 10.1261/rna.538907. Epub 2007 Jun 21.
10
2'-O-methyl-modified RNAs act as TLR7 antagonists.2'-O-甲基修饰的RNA可作为Toll样受体7拮抗剂。
Mol Ther. 2007 Sep;15(9):1663-9. doi: 10.1038/sj.mt.6300240. Epub 2007 Jun 19.